Literature DB >> 16935430

Metastatic colorectal cancer.

Piercarlo Saletti1, Franco Cavalli.   

Abstract

Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can provide a significant hope for long term survival, and a subset of patients might benefit from perioperative approaches. More recently, specific molecular processes have been targeted for therapeutic interventions, and encouraging results have been achieved using inhibitors of the Epidermal Growth Factor Receptor and the Vascular Endothelial Growth Factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16935430     DOI: 10.1016/j.ctrv.2006.07.005

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  5 in total

1.  Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Authors:  Sunil K Geevarghese; David A Geller; Hans A de Haan; Markus Hörer; Anette E Knoll; Axel Mescheder; John Nemunaitis; Tony R Reid; Daniel Y Sze; Kenneth K Tanabe; Hoda Tawfik
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

2.  Effects of miR-489 targeting on SOX4 gene on proliferation and apoptosis of human hepatocellular carcinoma cells.

Authors:  Bing Wang; Wang-Xun Jin; Yun-Li Zhang; Ling Huang; Hai-Bin Ni; Dilong Fang
Journal:  Afr Health Sci       Date:  2020-09       Impact factor: 0.927

3.  Survival of metastatic colorectal cancer patients treated with chemotherapy in Alberta (1995-2004).

Authors:  Yiqun Chen; Zhenguo Qiu; Anmmd Kamruzzaman; Tom Snodgrass; Andrew Scarfe; Heather E Bryant
Journal:  Support Care Cancer       Date:  2009-05-15       Impact factor: 3.603

4.  Molecularly characterised xenograft tumour mouse models: valuable tools for evaluation of new therapeutic strategies for secondary liver cancers.

Authors:  Daniela Mischek; Ralf Steinborn; Helga Petznek; Christoph Bichler; Kurt Zatloukal; Michael Stürzl; Walter H Günzburg; Christine Hohenadl
Journal:  J Biomed Biotechnol       Date:  2009-03-15

5.  A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer.

Authors:  O A Khan; M Ranson; M Michael; I Olver; N C Levitt; P Mortimer; A J Watson; G P Margison; R Midgley; M R Middleton
Journal:  Br J Cancer       Date:  2008-05-13       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.